|
|
|
| The Prokaryotic Expression of Recombinant Murine Interlukin (IL)-33 and Its Mucosal Immunization Affect as Adjuvant |
| FENG Xue-jun1,2,3, LONG Qiong1,2,3, TANG Zeng-hua1,2,3, HUANG Wei-wei1,2,3, LIU Cun-bao1,2,3, YANG Xu1,2,3, SUN Wen-jia1,2,3, BAI Hong-mei1,2,3, MA Yan-bing1,2,3 |
1 Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming 650118, China;
2 Yunnan Key Laboratory of Vaccine Research & Developent on Severe Infection Disease, Kunming 650118, China;
3 Yunnan Engineering Research of Vaccine Research and Development on Severe Infection Disease, Kunming 650118, China |
|
|
|
Abstract Objective:Interleukin(IL)-33 has important immunoregulatory effects on immune cells, such as dentritic cells, macropphage and T cells. The purpose is to prepare recombinant murine IL-33 in E.coli cells, and investigate the potentials and characteristics of IL-33 to be employed as an adjuvant in mucosal immunization. Methods:The expression of fusion protein thioredoxin/IL-33 was induced by IPTG in DH5α cells, and the purification was performed through a chromatography procedure consists of Q-Sepharose ionic exchange and Ni++ chelating affinity. And then, mature IL-33 was released from the fusion protein by enterokinase treatment. The recombinant HBcAg was combined with IL-33 or not, and used to immunize mice intranasally. HBcAg-specific IgA, IgG1 and IgG2a were detected with ELISAs. Results:Purified IL-33 displayed the similar bioactivity of stimulating RAW264.7 to express TNF-α as commercially derived recombinant IL-33. Purified IL-33 which served as an adjuvant significantly enhanced the HBcAg-specific IgA response in multiple mucosal tissues, as well as IgG1 levels in serum and bronchial alveolar lavage fluid, whereas reduced IgG2a levels. Conclusion:Active IL-33 is successfully prepared from E.coli cells, and has a potential to be used as a molecular adjuvant in mucosal immunization.
|
|
Received: 01 November 2016
Published: 25 April 2017
|
|
|
|
Cite this article:
FENG Xue-jun, LONG Qiong, TANG Zeng-hua, HUANG Wei-wei, LIU Cun-bao, YANG Xu, SUN Wen-jia, BAI Hong-mei, MA Yan-bing. The Prokaryotic Expression of Recombinant Murine Interlukin (IL)-33 and Its Mucosal Immunization Affect as Adjuvant. China Biotechnology, 2017, 37(4): 26-32.
URL:
https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20170404 OR https://manu60.magtech.com.cn/biotech/Y2017/V37/I4/26
|
|
|
[1] Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 2005,23(5):479-490.
[2] Moussion C, Ortega N, Girard J P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo:a novel ‘alarmin’? PLoS One, 2008,3(10):e3331.
[3] Komai-Koma M, Xu D, Li Y, et al. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol, 2007,37(10):2779-2786.
[4] Su Z, Lin J, Lu F, et al. Potential autocrine regulation of interleukin-33/ST2 signaling of dendritic cells in allergic inflammation. Mucosal Immunology, 2013,6(5):921-930.
[5] Luzina I G, Pickering E M, Kopach P, et al. Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. Journal of Immunology, 2012,189(1):403-410.
[6] Bourgeois E, Van L P, Samson M, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol, 2009,39(4):1046-1055.
[7] Bonilla W V, Frohlich A, Senn K, et al. The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science, 2012,335(6071):984-989.
[8] Gao X, Wang X, Yang Q, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. Journal of Immunology, 2015,194(1):438-445.
[9] Villarreal D O, Wise M C, Walters J N, et al. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res, 2014,74(6):1789-1800.
[10] Froidure A, Vandenplas O, D'Alpaos V, et al. Persistence of asthma following allergen avoidance is associated with proTh2 myeloid dendritic cell activation. Thorax, 2015,70(10):967-973.
[11]. Chu Xiaojie,Li Yang,Long Qiong,et al.Development of a HPV16 E7 CTLs peptides-based virus-like particle therapertic vaccine.China Biotechnology,2015,35(2):45-51.
[12] Gao K, Li X, Zhang L, et al. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Letters, 2013,335(2):463-471.
[13] Bagarazzi M L, Yan J, Morrow M P, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Science Translational Medicine, 2012,4(155):138. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
